Bacteriophage preparations and methods of use thereof
Inventors
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Intrlytix Inc • Zoctis Server LLC • Intralytix Inc • Zoetis Services LLC
MemberIntralytixIntralytixIntralytix is a biotechnology company specializing in bacteriophage-based solutions for controlling pathogenic bacteria in food safety, human and animal health, dietary supplements, environmental sanitation, and veterinary applications. The company utilizes lytic bacteriophages for targeted, non-chemical interventions and operates with in-house cGMP manufacturing, a broad patent portfolio, and ongoing clinical research, applying AI and machine learning in phage discovery and process optimization. Intralytix supports industry and academic progress through conference sponsorships and collaborative projects.
Intralytix is a biotechnology company specializing in bacteriophage-based solutions for controlling pathogenic bacteria in food safety, human and animal health, dietary supplements, environmental sanitation, and veterinary applications. The company utilizes lytic bacteriophages for targeted, non-chemical interventions and operates with in-house cGMP manufacturing, a broad patent portfolio, and ongoing clinical research, applying AI and machine learning in phage discovery and process optimization. Intralytix supports industry and academic progress through conference sponsorships and collaborative projects.
Publication Number
US-9320795-B2
Publication Date
2016-04-26
Expiration Date
Abstract
Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality of Clostridium species strains, in particular C. perfringens, C. septicum and C. difficile. In one embodiment, a purified bacteriophage preparation includes four or more C. perfringens-specific bacteriophage, wherein each bacteriophage has lytic activity against at least five Clostridium species strains. In another embodiment, the purified bacteriophage preparation includes five or more C. perfringens-specific bacteriophage. The invention also relates to the use of purified bacteriophage preparation in combination with antibiotics for the treatment of animals including poultry. The invention also relates to the use of the purified bacteriophage preparations as treatments effective against antibiotic-resistant strains of Clostridium.
Core Innovation
The invention provides a purified bacteriophage preparation for reducing mortality in poultry due to C. perfringens infections. The preparation comprises four or more C. perfringens-specific bacteriophage selected from CPAS-7 (PTA-8478), CPAS-12 (PTA-8479), CPAS-15 (PTA-8480), CPAS-16 (PTA-8481), and CPLV-42 (PTA-8483), and is formulated in a citrate-phosphate-thiosulfate buffer.
Each bacteriophage has lytic activity against at least 5 strains of a Clostridium species. In one formulation, the lytic activity includes antibiotic resistant Clostridium strains.
The invention also provides a composition that combines the purified bacteriophage preparation with an antibiotic. The composition includes the purified bacteriophage preparation, an antibiotic, and a citrate-phosphate-thiosulfate buffer.
Claims Coverage
The independent claims cover three related concepts: a purified bacteriophage preparation in citrate-phosphate-thiosulfate buffer for reducing poultry mortality due to C. perfringens infections, the same preparation with lytic activity targeting antibiotic resistant Clostridium strains, and a composition combining the purified bacteriophage preparation with an antibiotic plus citrate-phosphate-thiosulfate buffer. Across these independents, the claims require four or more specified C. perfringens-specific bacteriophages with lytic activity against at least 5 Clostridium species strains.
Purified bacteriophage preparation in citrate-phosphate-thiosulfate buffer for reducing poultry mortality due to C. perfringens infections
A purified bacteriophage preparation comprising four or more C. perfringens-specific bacteriophage selected from CPAS-7 (PTA-8478), CPAS-12 (PTA-8479), CPAS-15 (PTA-8480), CPAS-16 (PTA-8481), and CPLV-42 (PTA-8483), wherein each bacteriophage has lytic activity against at least 5 strains of a Clostridium species and the preparation is formulated in a citrate-phosphate-thiosulfate buffer.
Purified bacteriophage preparation targeting antibiotic resistant Clostridium strains in citrate-phosphate-thiosulfate buffer
A purified bacteriophage preparation comprising four or more C. perfringens-specific bacteriophage selected from CPAS-7 (PTA-8478), CPAS-12 (PTA-8479), CPAS-15 (PTA-8480), CPAS-16 (PTA-8481), and CPLV-42 (PTA-8483), wherein each bacteriophage has lytic activity against at least 5 strains of a Clostridium species which are antibiotic resistant and the preparation is formulated in a citrate-phosphate-thiosulfate buffer.
Composition combining purified bacteriophage preparation, antibiotic, and citrate-phosphate-thiosulfate buffer
A composition comprising the purified bacteriophage preparation, an antibiotic, and a citrate-phosphate-thiosulfate buffer, wherein the purified bacteriophage preparation comprises four or more C. perfringens-specific bacteriophage selected from CPAS-7 (PTA-8478), CPAS-12 (PTA-8479), CPAS-15 (PTA-8480), CPAS-16 (PTA-8481), and CPLV-42 (PTA-8483), and each bacteriophage has lytic activity against at least 5 strains of a Clostridium species.
Overall, the claim set is centered on purified bacteriophage preparations and an antibiotic-containing composition that use four or more specified C. perfringens-specific bacteriophages. The preparations require lytic activity against at least 5 Clostridium species strains and are formulated in a citrate-phosphate-thiosulfate buffer, with one independent claim requiring the targeted strains to be antibiotic resistant.
Stated Advantages
Reducing mortality in poultry due to C. perfringens infections.
Documented Applications
Reducing mortality in poultry due to C. perfringens infections.
Reducing mortality in poultry due to C. perfringens infections when Clostridium strains are antibiotic resistant.
A composition that combines the purified bacteriophage preparation with an antibiotic for reducing poultry mortality due to C. perfringens infections.
Interested in licensing this patent?